Achieve Life Sciences (ACHV) EBITDA (2010 - 2026)
Achieve Life Sciences (ACHV) recorded quarterly EBITDA of -$10.2 million in Q1 2026, up 29.5% on a QoQ basis from -$14.4 million in Q3 2025, and up 20.82% year-over-year from -$8.4 million in Q1 2025.
Achieve Life Sciences (ACHV) EBITDA (2010 - 2026) Analysis & Trends
Achieve Life Sciences has disclosed EBITDA across 15 years of filings, most recently posting -$10.2 million for Q1 2026.
- Quarterly EBITDA rose 20.82% year-over-year to -$10.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$50.2 million (down 24.69% YoY) and the FY2019 annual result came in at -$16.4 million, down 29.23% from the prior year.
- EBITDA advanced to -$10.2 million in Q1 2026, from -$14.4 million in the prior quarter.
- Over five years, EBITDA peaked at -$6.5 million in Q1 2024 and troughed at -$14.4 million in Q3 2025.
- A 4-year average of -$10.3 million and a median of -$10.2 million in 2026 frame the typical range for EBITDA.
- Annual changes were most pronounced in 2025 — EBITDA slumped 97.91% — and 2026, when it gained 20.82%.
- Tracing ACHV's EBITDA over 4 years: stood at -$7.1 million in 2023, then slumped by 74.87% to -$12.4 million in 2024, then retreated by 16.13% to -$14.4 million in 2025, then grew by 29.5% to -$10.2 million in 2026.
- Business Quant data shows ACHV's EBITDA at -$10.2 million in Q1 2026, -$14.4 million in Q3 2025, and -$12.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | -14.44 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | -3.82 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | -65.83 Mn |
| 10 | Achieve Life Sciences | 93.71 Mn | 63.22 Mn | - | -10.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.18 Mn |
| Sep 30, 2025 | -14.44 Mn |
| Jun 30, 2025 | -12.72 Mn |
| Mar 31, 2025 | -12.85 Mn |
| Sep 30, 2024 | -12.43 Mn |
| Jun 30, 2024 | -8.47 Mn |
| Mar 31, 2024 | -6.49 Mn |
| Sep 30, 2023 | -7.11 Mn |
| Jun 30, 2023 | -8.24 Mn |
| Jun 30, 2020 | -2.92 Mn |
| Mar 31, 2020 | -3.32 Mn |
| Dec 31, 2019 | -3.19 Mn |
| Sep 30, 2019 | -3.67 Mn |
| Jun 30, 2019 | -3.62 Mn |
| Mar 31, 2019 | -5.90 Mn |
| Dec 31, 2018 | -3.64 Mn |
| Sep 30, 2018 | -3.24 Mn |
| Jun 30, 2018 | -2.79 Mn |
| Mar 31, 2018 | -3.02 Mn |
| Dec 31, 2017 | -3.74 Mn |